Treatment strategies for space motion sickness were compared using the results of postflight oral debriefings. Standardized questionnaires were administered to all crewmembers immediately following Space Shuttle flights by NASA flight surgeons. Cases of space motion sickness were graded as mild, moderate, or severe based on published criteria, and medication effectiveness was judged based on subjective reports of symptom relief. Since October 1989, medication effectiveness is reported inflight through private medical conferences with the crew. A symptom matrix was analyzed for nineteen crewmembers treated with an oral combination of scopolomine and dextroamphetamine (scopdex) and fifteen crewmembers treated with promethazine delivered by intramuscular or suppository routes. Scopdex has been given preflight as prophylaxis for space motion sickness but analysis showed delayed symptom presentation in nine crewmembers or failed to prevent symptoms in seven.


    Access

    Access via TIB

    Check availability in my library


    Export, share and cite



    Title :

    Comparison of treatment strategies for space motion sickness


    Contributors:

    Publication date :

    1991-10-01


    Type of media :

    Conference paper


    Type of material :

    No indication


    Language :

    English




    Comparison of treatment strategies for space motion sickness

    Davis, J. R. / Jennings, R. T. / Beck, B. G. | NTRS | 1993



    Space motion sickness

    Homick, J. L. | NTRS | 1979



    Space Motion Sickness Status Report

    Kutyna, Frank | SAE Technical Papers | 1986